Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Prevention of acute sickle cell crisis: review of the NEJM report
source: Practical Pain Management
year: 2016
authors: Leonard Goldstein, Victoria A. Troncoso, Roya Vahdatinia
summary/abstract:A recent article in the New England Journal of Medicine presented the results of a phase 2 clinical trial that found positive results for the efficacy and safety of crizanlizumab, a novel pharmaceutical agent currently in pipeline development by Selexys Pharmaceuticals.
The drug, designed to block the underlying mechanism of acute painful crisis in patients suffering from sickle-cell disease, could be one of the first and most effective medications of its kind. For all the details on the Phase 2 research, read the original Practical Pain Management report.
In this commentary, Leonard B. Goldstein, DDS, PhD, and colleagues review the research and provide their own opinion on the prospect of a novel pharmaceutical agents for patients suffering from sickle cell disease.
read more
Related Content
-
ADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
-
Reproductive Health CHOICES for Young Adults with Sickle Cell Disease or Trait: Randomized Controlled Trial Outcomes...Interventions to assist reproductive hea...
-
Albuminuria, serum antioxidant enzyme levels and markers of hemolysis and inflammation in steady state children with...BACKGROUND: Oxidative stress is thought ...
-
Randomized Trials Needed to Assess Benefits of Salmonella Vaccines in SCD Patients, Study SaysRandomized controlled trials are needed ...
-
Differences in Brain Oxygen Supply May Explain Silent Strokes in SCD PatientsBrain oxygen supply is different in diff...
-
American Society of Hematology to launch sickle cell disease clinical trials networkThe American Society of Hematology (AS...
-
Providing Expert Care for Pregnant Sickle Cell Patienthttps://www.youtube.com/watch?v=rTebitxq...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.